SIGA Technologies, Inc. - 10-Q Summary (Q1 2006)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2006. SIGA Technologies, Inc. is a bio-defense company focused on the discovery and development of products against biological warfare agents (e.g., Smallpox, Arenaviruses) and serious infectious diseases. The Company has no commercial products and relies on government grants, contracts, and financing to fund operations. The financial statements are prepared on a going concern basis, contingent upon the success of R&D programs and the ability to secure additional financing.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Revenues | $1,394,454 | $1,458,565 |
| Operating Expenses | $2,708,747 | $2,571,387 |
| Operating Loss | $(1,314,293) | $(1,112,822) |
| Net Loss | $(2,833,660) | $(1,107,425) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $2,478,102 | $1,031,101 |
| Net Cash Provided by Operating Activities | $39,910 | $(626,372) |
| Total Debt (Notes Payable) | $1,187,345 | Not Disclosed |
Note: Total Debt includes $1,107,520 in current notes payable and $79,825 in non-current notes payable.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by approximately $64,000 (4.4%) primarily due to the expiration of the Saint Louis University agreement in February 2006, partially offset by revenue from a new USAF agreement.
- Significant Non-Cash Loss: Net loss increased significantly due to a $1.526 million non-cash charge representing the increase in the fair market value of common stock rights and warrants issued in November 2005.
- Operating Expenses: SG&A expenses increased by $97,000, driven by $92,000 in non-cash share-based compensation (due to SFAS 123(R) adoption), $115,000 in severance for the former CEO, and higher legal fees related to a planned merger. R&D expenses increased by $106,000 due to workforce expansion.
- Liquidity Improvement: Cash balances increased by $705,613, driven by $1.0 million in proceeds from a new Bridge Note and a shift to positive operating cash flow ($39,910) compared to a deficit in the prior year.
Guidance, Outlook, and Risks
- Merger Activity: SIGA entered into a term sheet to merge with PharmAthene, Inc. Shareholders are expected to own approximately 32% of the combined entity.
- Financing: The Company entered a Bridge Note Purchase Agreement with PharmAthene for $3.0 million in 8% notes. Two notes of $1.0 million each were issued in March and April 2006, with a third expected in May 2006.
- Liquidity Outlook: Management believes existing cash and anticipated funding (including the remaining Bridge Note and government grants) will support operations beyond June 30, 2007. A cost-reduction plan exists if funding is insufficient.
- R&D Status: The lead product, SIGA-246 (anti-smallpox), received FDA Fast-Track status. Estimated costs to complete the program range from $15 million to $20 million over 12 to 36 months.
- Legal Proceedings: Four Star Group filed a lawsuit alleging breach of contract and tortious interference, seeking damages believed to exceed $700,000. SIGA intends to contest the claims vigorously.
- Accounting Change: The Company adopted SFAS 123(R) on January 1, 2006, resulting in the recognition of share-based compensation expense ($121,425 for the quarter).
Investor Verification Checklist
- Merger Completion: Verify the status of the definitive merger agreement with PharmAthene, Inc. and shareholder approval timelines.
- Bridge Note Funding: Confirm the receipt of the third $1.0 million note payment scheduled for May 2006.
- Legal Exposure: Monitor the outcome of the Four Star Group litigation and potential financial impact.
- Grant Renewals: Assess the status of NIH SBIR grants and USAF contracts, which constitute the majority of revenue.
- Cash Burn Rate: Evaluate the sufficiency of the $2.48 million cash balance against the projected $15-$20 million cost to complete the SIGA-246 program.